Nordea Investment Management AB Increases Stake in DaVita Inc. $DVA

Nordea Investment Management AB raised its position in shares of DaVita Inc. (NYSE:DVA) by 1.8% in the third quarter, Holdings Channel reports. The firm owned 286,585 shares of the company’s stock after acquiring an additional 5,193 shares during the quarter. Nordea Investment Management AB’s holdings in DaVita were worth $37,864,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Hantz Financial Services Inc. increased its position in shares of DaVita by 48.1% during the second quarter. Hantz Financial Services Inc. now owns 231 shares of the company’s stock valued at $33,000 after acquiring an additional 75 shares in the last quarter. Mid American Wealth Advisory Group Inc. purchased a new stake in DaVita during the 2nd quarter valued at $36,000. Canada Pension Plan Investment Board bought a new stake in shares of DaVita in the 2nd quarter worth $43,000. Ameritas Advisory Services LLC purchased a new position in shares of DaVita in the second quarter worth $47,000. Finally, Employees Retirement System of Texas purchased a new position in shares of DaVita in the second quarter worth $49,000. Institutional investors own 90.12% of the company’s stock.

DaVita Stock Down 0.7%

Shares of NYSE:DVA opened at $103.71 on Thursday. The stock has a market capitalization of $7.32 billion, a PE ratio of 10.68, a price-to-earnings-growth ratio of 0.64 and a beta of 0.99. The firm’s 50 day moving average price is $116.83 and its 200-day moving average price is $128.25. DaVita Inc. has a twelve month low of $101.00 and a twelve month high of $179.60.

DaVita (NYSE:DVA) last announced its earnings results on Wednesday, October 29th. The company reported $2.51 EPS for the quarter, missing analysts’ consensus estimates of $3.17 by ($0.66). The business had revenue of $3.42 billion for the quarter, compared to analysts’ expectations of $3.43 billion. DaVita had a net margin of 5.80% and a negative return on equity of 13,370.89%. The firm’s quarterly revenue was up 4.8% on a year-over-year basis. During the same period in the prior year, the company posted $2.59 earnings per share. DaVita has set its FY 2025 guidance at 10.350-11.150 EPS. Analysts expect that DaVita Inc. will post 10.76 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

DVA has been the subject of several research analyst reports. Barclays reduced their price objective on DaVita from $149.00 to $143.00 and set an “equal weight” rating for the company in a report on Thursday, October 30th. Zacks Research upgraded shares of DaVita from a “strong sell” rating to a “hold” rating in a research note on Friday, November 28th. UBS Group reissued a “buy” rating on shares of DaVita in a report on Monday, December 15th. Wall Street Zen cut shares of DaVita from a “buy” rating to a “hold” rating in a report on Saturday, October 11th. Finally, Truist Financial decreased their target price on shares of DaVita from $140.00 to $128.00 and set a “hold” rating for the company in a research note on Monday, January 5th. One analyst has rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $145.60.

DaVita Company Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.